I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive
platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform
design, agents will be identified with a signal suggesting a big impact on reducing mortality
and the need for, as well as duration, of mechanical ventilation.
Phase:
Phase 2
Details
Lead Sponsor:
QuantumLeap Healthcare Collaborative
Collaborators:
Columbia University Emory University Georgetown University Hoag Memorial Hospital Presbyterian Kalispell Regional Medical Center Long Beach Memorial Medical Center Main Line Health Montefiore Medical Center Northwestern University Sanford Health University of Alabama at Birmingham University of California, Davis University of California, San Diego University of California, San Francisco University of Colorado, Denver University of Iowa University of Minnesota University of Pennsylvania University of Southern California Wake Forest University Health Sciences Yale University